Is there breast implant-associated cancer (BIA-ALCL)?

January 09, 2019 – Women should be alerted: Is there a thing like breast implant associated cancer (BIA-ALCL)? Yes, there is. Not every woman with a breast implant will get it, however. In fact, BIA-ALCL seems to be a rather rare condition; unfortunately, there is not yet a possibility to know prospectively who are the unlucky women who will be affected.

Most cases of breast implant-associated ALCL (BIA-ALCL) occur in women with textured breast implants.

BIA-ALCL is a rare cancer of the immune system. It is not breast cancer, which forms from cells in the breast, but instead a cancer that grows in the fluid and scar tissue that forms around a breast implant. The most common symptom of breast implant associated cancer is swelling of a breast caused by fluid build-up, but in some cases it may appear as a lump in the breast or armpit.

BIA-ALCL  will not be detected by a mammogram, and is usually tested for by analysis of a sample of the fluid around the implant. If you develop swelling of an implanted breast, your doctor will send you for an ultrasound scan to see if this is due to a fluid collection. If the ultrasound shows that fluid is present, a sample of the fluid will be removed and sent to a laboratory for analysis. Most fluid build-ups are not due to ALCL, but the laboratory test will be able to tell for sure.

 Most reported cases of BIA-ALCL  involve patients who have had a textured implant inserted at some point in their life. Patients with smooth implants may still develop this cancer if they have previously had a textured implant or tissue expander inserted. Based on current evidence, experts do not think BIA-ALCL  is related to either the contents (saline/silicone) or shape (round/teardrop) of the implant. However, BIA-ALCL  does occur at far higher rates among women with textured rather than smooth-surfaced implants. Thasso post had already a post on the possible price, the beauty of women has to pay on breast implants of this kind.

Noteworthy, there have been more than 600 cases of BIA-ALCL reported worldwide. In a very recent development, in December 2018 France’s National Agency for the Safety of Medicines and Health Products (ANSM) announced that Allergan’s textured breast implants can no longer be marketed in France and elsewhere in Europe (thasso post reported on it). Thus, according to ANSM, Allergan, one of the world’s largest manufacturers of breast implants, has been unable to renew safety certificates, known as CE marks, for two of its textured surfaces, namely Microcell and Biocell, used in products such as its Natrelle range of breast implants. According to EU-regulations, breast implants, like all medical devices, must have CE marks in order to be sold in 33 European countries. This loss of Allergan’s certificates comes after French regulators at ANSM last month recommended smooth-shell breast implants be used instead of textured-shell products, referring to links between the latter and anaplastic large cell lymphoma (i.e., BIA-ALCL) which in turn would impact on the health aspect for the CE registration of the textured breast implants (considered medical devices) in question.

Also the American Food and Drug Administration (FDA) is tracking the relationship between textured breast implants and breast implant-associated ALCL (BIA-ALCL).  According to their data base, breast implants, regardless of surface texture, are associated with a small risk of BIA-ALCL.  There appear to be multiple factors involved in the development of BIA-ALCL such as patient characteristics, operative procedure history, breast implant characteristics, including surface characteristics, and duration the breast implant is, or has been, in place. FDA will in due time inform about their findings too. It will be interesting to see, if a higher incidence of BIA-ALCL in woman whit textured breast implants. It would also be most interesting to find prospective firm risk factors (biomarkers, genetic predispositions, etc.) which would put patients at the highest risk for the development of BIA-ALCL.

See here a discussion of aspects surrounding BIA-ALCL:

Print Friendly, PDF & Email

Tags: , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion

Comment

No comments yet

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • The genetics of side-effects November 25, 2020
    Henk-Jan Guchelaar knows all too well the serious problems that the side-effects of medication can cause. As a professor of clinical pharmacy at the University of Leiden in the Netherlands, he has spent the last two decades trying to get the link between medicine and our genes recognised more widely.
  • Gene donors at high risk for cancer received feedback November 25, 2020
    Researchers at the Estonian Genome Center at the University of Tartu studied how people at high risk for breast, ovarian or prostate cancer responded to the feedback of genetic findings. Gene donors who chose to receive results appreciated being contacted and considered the information provided to be valuable. Authors find that knowing more about people's […]
  • Researchers reveal how genetic variations are linked to COVID-19 disease severity November 25, 2020
    Even as tens of thousands of Americans test positive for COVID-19 each day, physicians still aren't sure why some people experience mild to no symptoms while others become critically ill. New research led by Robert E. Gerszten, MD, Chief of the Division of Cardiovascular Medicine at Beth Israel Deaconess Medical Center (BIDMC) sheds new light […]
  • Study identifies new functions in the gene that causes Machado-Joseph disease November 25, 2020
    Ataxia is a minority disease with genetic origins, known for its neuromuscular alterations due to the selective loss of neurons in the cerebellum, the organ of our nervous systems which controls movement and balance. UB researchers have identified new functions in the ataxin 3 gene (ATXN3)–which causes Machado-Joseph disease, the most common type of ataxia– […]
  • BICRA gene provides answers to patients, doctors and scientists November 23, 2020
    Physicians and scientists are constantly on the lookout for new disease genes that can help them understand why patients have undiagnosed medical problems. Often the first clues come from genetic testing that reveals a change or mutation in a gene that they see in a child but not their parents. This is exactly what led […]
  • Understanding traditional Chinese medicine can help protect species November 26, 2020
    Demystifying traditional Chinese medicine for conservationists could be the key to better protecting endangered species like pangolins, tigers and rhino, according to University of Queensland-led researchers. UQ PhD candidate Hubert Cheung said efforts to shift entrenched values and beliefs about Chinese medicine are not achieving conservation gains in the short term.
  • Satellite images confirm uneven impact of climate change November 26, 2020
    University of Copenhagen researchers have been following vegetation trends across the planet's driest areas using satellite imagery from recent decades. They have identified a troubling trend: Too little vegetation is sprouting up from rainwater in developing nations, whereas things are headed in the opposite direction in wealthier ones. As a result, the future could see […]
  • Survival protein may prevent collateral damage during cancer therapy November 25, 2020
    Australian researchers have identified a protein that could protect the kidneys from 'bystander' damage caused by cancer therapies. The 'cell survival protein', called BCL-XL, was required in laboratory models to keep kidney cells alive and functioning during exposure to chemotherapy or radiotherapy. Kidney damage is a common side effect of these widely used cancer therapies, […]
  • New discovery by SMART allows early detection of shade avoidance syndrome in plants November 25, 2020
    Researchers from Singapore-MIT Alliance for Research and Technology (SMART) have developed a tool that allows early detection of shade avoidance syndrome (SAS) in plants using Raman spectroscopy in significantly less time compared to conventional methods. The discovery can help farmers better monitor plant health and lead to improved crop yield.
  • Psychological factors contributing to language learning November 25, 2020
    Motivation for language learning is a system of cognitive, emotional, and personality-related characteristics.
Top